Metabolomics

Dataset Information

0

Mesenchymal stromal cells secretome restores bioenergetic and redox homeostasis in human proximal tubule cells after ischemic injury


ABSTRACT:

BACKGROUND: Ischemia/reperfusion injury (IRI) is the leading cause of acute kidney injury (AKI). The current standard of care focuses on supporting kidney function, stating the need for more efficient and targeted therapies to enhance repair. Mesenchymal Stromal Cells (MSCs) and their secretome, either as conditioned medium (CM) or extracellular vesicles (EVs), have emerged as promising options for regenerative therapy, however, their full potential in treating AKI remains unknown.

METHODS: In this study, we employed an in vitro model of chemically-induced ischemia using antimycin A combined with 2-deoxy-D-glucose to induce ischemic injury in proximal tubule epithelial cells. Afterwards, we evaluated the effects of MSC secretome, CM or EVs obtained from adipose tissue, bone marrow and umbilical cord, on ameliorating the detrimental effects of ischemia. To assess the damage and treatment outcomes, we analyzed cell morphology, mitochondrial health parameters (mitochondrial activity, ATP production, mass and membrane potential) and overall cell metabolism by metabolomics.

RESULTS: Our findings show that ischemic injury caused cytoskeletal changes confirmed by disruption of the F-actin network, energetic imbalance as revealed by a 50% decrease in the oxygen consumption rate, increased oxidative stress, mitochondrial dysfunction and reduced cell metabolism. Upon treatment with MSC secretome, the morphological derangements were partly restored and ATP production increased by 40-50%, with umbilical cord-derived EVs being most effective. Furthermore, MSC treatment led to phenotype restoration as indicated by an increase in cell bioenergetics, including increased levels of glycolysis intermediates, as well as an accumulation of antioxidant metabolites.

CONCLUSION: Our in vitro model effectively replicated the in vivo-like morphological and molecular changes observed during ischemic injury. Additionally, treatment with MSC secretome ameliorated proximal tubule damage, highlighting its potential as a viable therapeutic option for targeting AKI.

INSTRUMENT(S): Liquid Chromatography MS - alternating - hilic

SUBMITTER: Joao Pedro Ferreira Faria 

PROVIDER: MTBLS6279 | MetaboLights | 2023-10-16

REPOSITORIES: MetaboLights

Dataset's files

Source:
Action DRS
MTBLS6279 Other
FILES Other
a_MTBLS6279_LC-MS_alternating_hilic_metabolite_profiling.txt Txt
i_Investigation.txt Txt
m_MTBLS6279_LC-MS_alternating_hilic_metabolite_profiling_v2_maf.tsv Tabular
Items per page:
1 - 5 of 6

Similar Datasets

2020-09-09 | GSE144622 | GEO
2019-02-13 | MSV000083439 | MassIVE
2021-12-31 | E-MTAB-9896 | biostudies-arrayexpress
2021-12-31 | E-MTAB-9900 | biostudies-arrayexpress
2024-01-26 | GSE207020 | GEO
2023-10-10 | GSE159701 | GEO
2021-06-16 | GSE171417 | GEO
2020-04-27 | GSE137293 | GEO
2021-09-08 | PXD011414 | Pride
2019-11-29 | GSE121191 | GEO